• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.37% Nasdaq Down0.31%

    Alseres Pharmaceuticals, Inc. (ALSE)

    -Other OTC
    65.00 0.00(0.00%) Nov 25
    ProfileGet Profile for:
    Alseres Pharmaceuticals, Inc.
    275 Grove Street
    Suite 2-400
    Auburndale, MA 02466
    United States - Map
    Phone: 508-497-2360
    Website: http://www.alseres.com

    Index Membership:N/A
    Full Time Employees:3

    Business Summary 

    Alseres Pharmaceuticals, Inc., a biotechnology company, together with its subsidiaries, focuses on developing therapeutic and diagnostic products primarily for disorders in the central nervous system. The company’s clinical product candidate, Altropane, is a molecular imaging program, which focuses on the diagnosis of Parkinsonian syndromes, including Parkinson’s disease, and dementia with lewy bodies. It has a license agreement with Navidea Biopharmaceuticals, Inc. to research, develop, and commercialize Altropane, an Iodine-123 radiolabeled imaging agent for the diagnosis of Parkinson’s disease and movement disorders. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alseres Pharmaceuticals, Inc.

    Key Executives 
    Mr. Peter G. Savas , 67
    Exec. Chairman, Chief Exec. Officer and Member of Fin. Committee
    Mr. Kenneth L. Rice Jr., J.D., LLM, MBA, 60
    Chief Financial Officer, Principal Accounting Officer, Exec. VP of Fin. & Admin., Sec. and In-House Counsel
    Mr. Sam Martin ,
    Director of Fin. and Corp. Compliance
    Dr. Noel Cusack Ph.D., 74
    Sr. VP of Preclinical Devel.
    Dr. Mark R. Hurtt M.D.,
    Chief Medical Officer
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders